Skip to main content
Smart Investors Daily
NE

NASDAQ · NEPH

Nephros, Inc.

Healthcare · Medical - Instruments & Supplies

$4.08

Down-$0.33 (-7.38%)

Updated Aug 23, 2026, 3:40 PM

SID Score

4.5/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
52.9M
P/E ratio
35.79
Dividend yield
0.00%
52-week range
$2.66 – $4.87
Volume
100.71K
Avg. volume
78.57K

Price performance

NEPH price history

1M range · 20 trading sessions · Daily adjusted prices

NEPH closed at $4.08 after 20 trading sessions, up 18.95% for the selected period.

Last close
$4.08
Period change
+18.95%
Period low
$3.24
Period high
$4.76
Daily close
View OHLC price history
NEPH OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 21, 2026$4.41$4.42$3.78$4.08100.71K
Aug 20, 2026$4.87$4.87$4.295$4.40544.89K
Aug 19, 2026$4.60$4.87$4.60$4.7619.62K
Aug 18, 2026$4.35$4.70$4.315$4.5918.92K
Aug 17, 2026$4.66$4.66$4.03$4.3281.51K
Aug 14, 2026$4.70$4.70$4.2301$4.62510.41K
Aug 13, 2026$4.41$4.70$4.35$4.6947.35K
Aug 12, 2026$4.41$4.4295$4.1565$4.3614.82K
Aug 11, 2026$4.46$4.515$4.00$4.2720.36K
Aug 10, 2026$4.41$4.7796$4.26$4.3828.37K
Aug 7, 2026$3.80$4.60$3.6206$4.2167.77K
Aug 6, 2026$3.495$3.59$3.495$3.5918.37K
Aug 5, 2026$3.57$3.58$3.4932$3.582.22K
Aug 4, 2026$3.41$3.75$3.41$3.596.37K
Aug 3, 2026$3.35$3.625$3.35$3.5158.16K
Jul 31, 2026$3.36$3.395$3.36$3.393.77K
Jul 30, 2026$3.41$3.50$3.28$3.5010.43K
Jul 29, 2026$3.55$3.55$3.24$3.240116.88K
Jul 28, 2026$3.41$3.50$3.20$3.5026.97K
Jul 27, 2026$3.65$3.65$3.3987$3.438.09K

Latest NEPH news

The latest Smart Investors Daily articles mentioning NEPH.

NEPH research

Overview

Company profile and research snapshot.

Company profile

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
NEPH recent ratings
DateFirmRatingTarget
Aug 8, 2025Maxim GroupBuy
Nov 12, 2024BenchmarkSpeculative Buy
May 15, 2024BenchmarkSpeculative Buy
Mar 8, 2024BenchmarkSpeculative Buy
Jan 26, 2021B. Riley FBRBuy
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.